Literature DB >> 33513748

NanoString Technology for Human Papillomavirus Typing.

Mangalathu S Rajeevan1, Sonya Patel1, Tengguo Li1, Elizabeth R Unger1.   

Abstract

High-throughput HPV typing assays with increased automation, faster turnaround and type-specific digital readout would facilitate studies monitoring the impact of HPV vaccination. We evaluated the NanoString nCounter® platform for detection and digital readout of 48 HPV types in a single reaction. NanoString (NS) used proprietary software to design CodeSets: type-specific probe pairs targeting 48 HPV types and the globin gene. We tested residual DNA extracts from epidemiologic specimens and defined samples (HPV plasmids at 10 to 104 copies/reaction) directly (No-PCR) as well as after L1 consensus PCR of 45 (PCR-45) or 15 cycles (PCR-15). Assay and interpretation followed NS recommendations. We evaluated analytic performance by comparing NanoString results for types included in prior assays: Roche Linear Array (LA) or HPV TypeSeq assay. No-PCR results on 40 samples showed good type-specific agreement with LA (k = 0.621) but sensitivity was 65% with lower limit of detection (LOD) at 104 plasmid copies. PCR-45 results showed almost perfect type-specific agreement with LA (k = 0.862), 82% sensitivity and LOD at 10 copies. PCR-15 results on 75 samples showed substantial type-specific agreement with LA (k = 0.796, 92% sensitivity) and TypeSeq (k = 0.777, 87% sensitivity), and LOD at 10 copies of plasmids. This proof-of-principle study demonstrates the efficacy of the NS platform with HPV CodeSet for type-specific detection using a low number of PCR cycles (PCR-15). Studies are in progress to evaluate assay reproducibility and analytic validation with a larger number of samples.

Entities:  

Keywords:  HPV detection; Linear Array; NanoString; PCR cycles; TypeSeq

Mesh:

Substances:

Year:  2021        PMID: 33513748      PMCID: PMC7911781          DOI: 10.3390/v13020188

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  32 in total

1.  Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).

Authors:  Penelope Gray; Tapio Luostarinen; Simopekka Vänskä; Tiina Eriksson; Camilla Lagheden; Irene Man; Johanna Palmroth; Ville N Pimenoff; Anna Söderlund-Strand; Joakim Dillner; Matti Lehtinen
Journal:  Int J Cancer       Date:  2019-02-28       Impact factor: 7.396

2.  Updating the PGMY primers and probes for improved detection of HPV68a: validation of version 2 of the PGMY-CHUV assay.

Authors:  C Estrade; R Sahli
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

3.  Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping.

Authors:  C Estrade; R Sahli
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

4.  Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.

Authors:  Sara E Oliver; Elizabeth R Unger; Rayleen Lewis; Darius McDaniel; Julia W Gargano; Martin Steinau; Lauri E Markowitz
Journal:  J Infect Dis       Date:  2017-09-01       Impact factor: 5.226

5.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

6.  Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).

Authors:  Penelope Gray; Johanna Palmroth; Tapio Luostarinen; Dan Apter; Gary Dubin; Geoff Garnett; Tiina Eriksson; Kari Natunen; Marko Merikukka; Ville Pimenoff; Anna Söderlund-Strand; Simopekka Vänskä; Jorma Paavonen; Eero Pukkala; Joakim Dillner; Matti Lehtinen
Journal:  Int J Cancer       Date:  2018-02-12       Impact factor: 7.396

7.  RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers.

Authors:  Joseph R Dobosy; Scott D Rose; Kristin R Beltz; Susan M Rupp; Kristy M Powers; Mark A Behlke; Joseph A Walder
Journal:  BMC Biotechnol       Date:  2011-08-10       Impact factor: 2.563

8.  Comparison of the Cobas 4800 HPV and HPV 9G DNA Chip Tests for Detection of High-Risk Human Papillomavirus in Cervical Specimens of Women with Consecutive Positive HPV Tests But Negative Pap Smears.

Authors:  Sun-Young Jun; Eun Su Park; Jiyoung Kim; Jun Kang; Jae Jun Lee; Yoonjin Bae; Sang-Il Kim; Lee-So Maeng
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

9.  Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes.

Authors:  Sarah Wagner; David Roberson; Joseph Boland; Aimée R Kreimer; Meredith Yeager; Michael Cullen; Lisa Mirabello; S Terence Dunn; Joan Walker; Rosemary Zuna; Carolina Porras; Bernal Cortes; Joshua Sampson; Rolando Herrero; Ana Cecilia Rodriguez; Wim Quint; Leen-Jan Van Doorn; Allan Hildesheim; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

10.  Human papillomavirus genotyping by Linear Array and Next-Generation Sequencing in cervical samples from Western Mexico.

Authors:  María Guadalupe Flores-Miramontes; Luis Alberto Torres-Reyes; Liliana Alvarado-Ruíz; Salvador Angel Romero-Martínez; Verenice Ramírez-Rodríguez; Luz María Adriana Balderas-Peña; Verónica Vallejo-Ruíz; Patricia Piña-Sánchez; Elva Irene Cortés-Gutiérrez; Luis Felipe Jave-Suárez; Adriana Aguilar-Lemarroy
Journal:  Virol J       Date:  2015-10-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.